Phase 1/2 Trial Confirms Safety With Repeated Dosing Supporting Further Development in Early-stage Disease and Combination Treatment Settings ATLANTA, GA - December 8, 2025 (NEWMEDIAWIRE) - GeoVax ...

Patent Protects Novel Application of Gedeptin Therapy Across Multiple Solid Tumor Types; Supports Expansion of Gedeptin ...

The first-line standard of care for HR-positive/HER2-negative breast cancer is cyclin-dependent kinase (CDK)4/6 inhibitors ...

The U.S. commercial launch of LYMPHIR (denileukin diftitox-cxdl), a novel cancer immunotherapy for adults with relapsed or ...

As big pharmas including Takeda and Novo Nordisk flee the cell therapy space and smaller biotechs shutter their operations, ...

Mycosis fungoides, the most prevalent CTCL subtype, accounts for the majority of cases. Although early-stage disease has a five-year survival rate of roughly 88%, it is a chronic cancer with ...

A study by researchers at the D’Or Institute for Research and Education in Rio de Janeiro, Brazil, suggests that blocking the microRNA known as miR-21 may significantly slow the growth and spread of ...

The US Patent and Trademark Office has issued a new patent (US Patent No. 12,472,263) on additional and novel formulations of ...

The U.S. FDA assigned a target action date of April 8, 2026PRINCETON, N.J.--(BUSINESS WIRE)--$BMY #FDA--Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA ...

Axatilimab showed a consistent safety profile in cGVHD patients, with no new safety signals and a decrease in TEAEs over time. The AGAVE-201 trial led to FDA approval of axatilimab at 0.3 mg/kg every ...

The global bioconjugation market is projected to grow at an estimated CAGR of close to 13% over the next five years. This growth is fueled by the rising need for targeted therapies, continuous ...

A 23-month-old with a history of Hirschsprung disease was referred for evaluation of a persistent, severe diaper rash ...